Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
AFMD: Affimed N.V.
2019-11-07 16:01:00
Affimed Announces FDA Clearance of IND to Commence First-in-Human Phase 1/2a Study of AFM24 for the Treatment of EGFR-Expressing Cancers
While looking at the support and resistance lines, it becomes clear the support lines are more consolidated while the resistance lines have a larger spread. This leave an interpretation that there's much more room for AFMD to grow rather than to fall. Additionally, beyond the technicals the EPS for the previous quarter left investors shocked because of the...
While analyzing the current support and resistance lines, I believe Affimed is ready to soar higher over the coming weeks. It's also worth noting that the recent EPS for the last quarter was significantly higher than the expected, leaving a lasting and big surprise for investors. Meanwhile, Affimed has presented at several conferences and proved that big news is...
After Piercing initial resistance, we are now consolidating with an uptick in volume, a buy stop above 2.95 should see more upside, Stop below consolidation @ 2.15. I am long from 2.00 and looking to add.
Affimed NV engages in discovering and developing of targeted cancer immunotherapies. Its pipelines include Innate Cell Engagers and T Cell Engagers. The company was founded in 2000 and is headquartered in Heidelberg, Germany.
AFMD
